ZYME · Zymeworks Inc.
$28.22
-0.77% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
31.3
Dividend yield
0.0%
Beta
1.17
Avg volume
1M
Employees
0K
Daily Change %
-0.77%
5 Days Change
13.62%
10 Days Change
13.44%
30 Days Change
3.42%
60 Days Change
-1.15%
Month to Day Change
9.55%
Year to Day Change
8.01%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ZYME
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
Citigroup
Buy$39.00
+38.2% vs priceJP Morgan
Overweight$33.00
+16.9% vs priceWells Fargo
Overweight$40.00
+41.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Truist Securities | Maintains | Buy | $32.00 → $34.00 |
| 2026-09-29 | Citigroup | Maintains | Buy | $38.00 → $39.00 |
| 2026-09-17 | Wolfe Research | Initiates | Outperform | $0.00 |
| 2026-09-03 | JP Morgan | Maintains | Overweight | $31.00 → $33.00 |
| 2026-08-26 | Citigroup | Maintains | Buy | $37.00 → $38.00 |
| 2026-08-26 | Citizens | Reiterates | Market Outperform | $32.00 |
| 2026-08-26 | HC Wainwright & Co. | Maintains | Buy | $51.00 → $55.00 |
| 2026-08-10 | B. Riley Securities | Reiterates | Buy | $40.00 → $44.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 4.4% above the 50-day MA ($27.04).
- bullish: Price vs 200-day MA: Trading 12.5% above the 200-day MA ($25.09).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.36) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($16.46) and high ($31.05).
ZYME Price Chart
Loading chart for ZYME…
Fundamentals
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.